My watch list  


Systematic (IUPAC) name
CAS number  ?
ATC code A03AA04
PubChem  ?
Chemical data
Formula C25H36NO5 
Mol. mass 430.5595 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Mebeverine HCI is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by Solvay Pharmaceuticals.

Mebeverine HCI presented in tablets (100mg or 135mg), capsules (200mg slow release), and liquid (10mg/ml).


Mode of Action

Mebeverine HCI belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mebeverine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE